Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Medtronic
Merck
Harvard Business School
McKinsey
Moodys

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

XIMINO Drug Profile

See Plans and Pricing

« Back to Dashboard

Which patents cover Ximino, and what generic alternatives are available?

Ximino is a drug marketed by Sun Pharm Inds Inc and is included in one NDA. There are six patents protecting this drug.

This drug has thirteen patent family members in ten countries.

The generic ingredient in XIMINO is minocycline hydrochloride. There are fifteen drug master file entries for this compound. Forty-eight suppliers are listed for this compound. Additional details are available on the minocycline hydrochloride profile page.

Drug patent expirations by year for XIMINO
Drug Prices for XIMINO

See drug prices for XIMINO

Recent Litigation for XIMINO

Identify potential future generic entrants

District Court Litigation
Case NameDate
Apotex Inc. v. Wyeth LLC2015-07-29
Medicis Pharmaceutical Corporation v. Alkem Laboratories Ltd.2012-12-05
Medicis Pharmaceutical Corporation v. Zydus Pharmaceuticals USA Inc.2012-06-04

See all XIMINO litigation

Pharmacology for XIMINO
Synonyms for XIMINO
(2E,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione hydrochloride
(2Z,4S,4aS,5aR,12aS)-2-[amino(hydroxy)methylidene]-4,7-bis(dimethylamino)-10,11,12a-trihydroxy-4a,5,5a,6-tetrahydro-4H-tetracene-1,3,12-trione hydrochloride
(4S-(4alpha,4aalpha,5aalpha,12aalpha))-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide monohydrochloride
(4S,12aS,4aS,5aR)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-4,5,6,12a,4a,5a-hexahydronaphthacene-2-carboxamide Hydrochloride
(4S,4aS,5aR,12aS)-4,7-bis(dimethylamino)-3,10,12,12a-tetrahydroxy-1,11-dioxo-1,4,4a,5,5a,6,11,12a-octahydrotetracene-2-carboxamide hydrochloride
[4S-(4?,4a?,5a?,12a?)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a,tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
[4S-(4|A,4a|A,5a|A,12a|A)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydro-1,11-dioxo-2-naphthacenecarboxamide Hydrochloride
[4S-(4|A,4a|A,5a|A,12a|A)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide monohydrochloride
[4S-(4a,4aa,5aa,12aa)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a,tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide
[4S-(4alpha,4aalpha,5aalpha,12aalpha)]-4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxonaphthacene-2-carboxamide monohydrochloride
0020414E5U
10118-90-8 (base)
10118-90-8 (Parent)
1071702-75-4
11006-27-2
1236362-29-0
13614-98-7
150231-24-6
2-Naphthacenecarboxamide, 4,7- bis(dimethylamino)-1,4,4a,5,5a,6,11,12a- octahydro-3,10,12,12a-tetrahydroxy-1,11dioxo-, monohydrochloride, [4S-(4alpha,4aalpha,5aalpha,12aalpha)]
2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, monohydrochloride
2-Naphthacenecarboxamide, 4,7-bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-, monohydrochloride, (4S-(4alpha,4aalpha,5aalpha,12aalpha))-
4,7-Bis(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,10,12,12a-tetrahydroxy-1,11-dioxo-2-naphthacenecarboxamide monohydrochloride
614M987
7-Dimethylamino-6-demethyl-6-deoxytetracycline, HCl
AB1009463
AC-22362
AC1NQY0N
AC1NSG07
Acnez
AKOS015951312
Arestin
Arestin (TN)
BC207859
BCP06597
C23H27N3O7.HCl
C23H28ClN3O7
CAS-13614-98-7
CCG-40107
CHEBI:50697
CHEMBL1200881
CS-1256
D00850
DSSTox_CID_24545
DSSTox_GSID_44545
DSSTox_RID_80306
DTXSID8044545
Dynacin
Dynacin (TN)
EINECS 237-099-7
FT-0082736
FT-0601821
FXFM-244
GLMUAFMGXXHGLU-VQAITOIOSA-N
HMS1568P12
HY-17412
J10198
KB-274624
Klinomycin
KS-00000XT8
Lederderm
LS-91518
LS-93852
M2288
MFCD00083669
MINO
Minocin
Minocin (TN)
Minocycline (hydrochloride)
Minocycline chloride
Minocycline HCl
MINOCYCLINE HYDROCHLORIDE
Minocycline hydrochloride (internal use)
Minocycline hydrochloride (JP17/USP)
Minocycline hydrochloride [USAN:JAN]
Minocycline hydrochloride [USP:JAN]
Minocycline hydrochloride, 97%
Minocycline hydrochloride, Antibiotic for Culture Media Use Only
Minocycline hydrochloride, crystalline
Minocycline hydrochloride, European Pharmacopoeia (EP) Reference Standard
Minocycline Hydrochloride, Pharmaceutical Secondary Standard; Certified Reference Material
Minocycline hydrochloride, United States Pharmacopeia (USP) Reference Standard
Minocycline, HCl
Minocycline, Hydrochloride
Minocyclinhydrochlorid
Minomax
Minomycin
Minomycin chloride
minomycin hydrochloride
MLS002548863
MolPort-003-666-235
MolPort-042-652-589
Mynocine
Mynocine hydrochloride
NC00460
NCGC00096006-01
NCGC00178854-03
NCGC00255988-01
NSC-757120
NSC757120
Periocline
Pharmakon1600-01500414
Prestwick_626
Q-201407
S051
s4226
SC-19210
SCHEMBL2537
SMR001906766
Solodyn
Solodyn (TN)
SPECTRUM1500414
SR-01000075625
SR-01000075625-1
ST24034766
Tox21_111250
Tox21_111250_1
Tox21_113183
Tox21_301590
Tri-mino
Tri-minocycline
UNII-0020414E5U
Vectrin
W-5076

US Patents and Regulatory Information for XIMINO

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sun Pharm Inds Inc XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012 RX No No   Start Trial   Start Trial Y   Start Trial
Sun Pharm Inds Inc XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-005 Jul 11, 2012 RX No No   Start Trial   Start Trial   Start Trial
Sun Pharm Inds Inc XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-002 Jul 11, 2012 DISCN No No   Start Trial   Start Trial   Start Trial
Sun Pharm Inds Inc XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012 RX No No   Start Trial   Start Trial   Start Trial
Sun Pharm Inds Inc XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-003 Jul 11, 2012 RX No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for XIMINO

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sun Pharm Inds Inc XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-005 Jul 11, 2012   Start Trial   Start Trial
Sun Pharm Inds Inc XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-001 Jul 11, 2012   Start Trial   Start Trial
Sun Pharm Inds Inc XIMINO minocycline hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 201922-003 Jul 11, 2012   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
AstraZeneca
McKinsey
Boehringer Ingelheim
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.